Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
Abbreviations
aHUS
ALL
ALS
aBC
AD
AIH
Advanced breast cancer
Atopic Dermatitis
Autoimmune hepatitis
atypical Hemolytic Uremic Syndrome
Acute lymphoblastic leukemia
Amyotrophic lateral sclerosis
IPF
JIA
LVEF
mCRPC
MDR
MDS
AMI
Acute myocardial infarction
MS
AML
Acute myeloid leukemia
WAMD
AS H2H
Ankylosing spondylitis head-to-head study versus adalimumab
NASH
BC
Breast cancer
nHCM
C3G
C3 glomerulopathy
nr-axSpA
CCF
Congestive cardiac failure
NSCLC
CLL
CML
CRC
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Colorectal cancer
PDR
PEF
PedPsO
Pediatric psoriasis
COPD
Chronic obstructive pulmonary disease
PNH
COSP
Chronic ocular surface pain
PsA
CRSWNP
CSU
Severe chronic rhinosinusitis with nasal polyps
RCC
Chronic spontaneous urticaria
PROS
CVRR-Lp(a)
CVRR-LDLC
DME
Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a)
Secondary prevention of cardiovascular events in patients with elevated levels of LDLC
Diabetic macular edema
RA
rMS
Idiopathic pulmonary fibrosis
Juvenile idiopathic arthritis
Left ventricular ejection fraction
Metastatic castration-resistant prostate cancer
Multi-drug resistant
Myelodysplastic syndrome
Multiple sclerosis
Wet (neovascular) age-related macular degeneration
Non-alcoholic steatohepatitis
Non-obstructive hypertrophic cardiomyopathy
Non-radiographic axial spondyloarthritis
Non-small cell lung cancer
Proliferative diabetic retinopathy
Preserved ejection fraction
Paroxysmal nocturnal haemoglobinuria
Psoriatic arthritis
Renal cell carcinoma
PIK3CA related overgrowth spectrum
Rheumatoid arthritis
Relapsing multiple sclerosis
ROP
Retinopathy of prematurity
DLBCL
FL
GCA
GVHD
HCC
HD
HFPEF
HF-REF
HNSCC
HS
ΙΑ
IgAN
iMN
Diffuse large B-cell lymphoma refractory
Follicular lymphoma
Giant cell arteritis
Graft-versus-host disease
Hepatocellular carcinoma
Huntington's disease
Chronic heart failure with preserved ejection fraction
Chronic heart failure with reduced ejection fraction
Head and neck squamous cell carcinoma
Hidradenitis suppurativa
Interim analysis
IgA nephropathy
Membranous nephropathy
RP
Retinitis pigmentosa
RVO
Retinal vein occlusion
SAA
SLE
SpA
SPMS
TNBC
T1DM
Type 1 Diabetes mellitus
SMA Type 1
SMA Type 2/3
Severe aplastic anemia
Systemic lupus erythematosus
Spinal muscular atrophy (IV formulation)
Spinal muscular atrophy (IT formulation)
Spondyloarthritis
Secondary progressive multiple sclerosis
Triple negative breast cancer
136 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation